gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · SNTIHealthcareBiotechnology

Senti Biosciences Holdings, Inc. Common Stock (SNTI)

$0.1645−6.85%
Close Nov 5, 2026 · split-adjusted
Nov 5, 2026$0.16▼ 91.42% in range
Nov 4, 2025Low $0.16 · High $2.39Nov 5, 2026
What changed · written from our data
As of Nov 5, 2026

Senti Biosciences Holdings closed at $0.16 on Nov 5, down 6.85%, within 0.0% of its 52-week closing low. Volume of 286.1K shares was 0.03× its 20-day average (below normal).

Split-adjusted performance: -50.2% over one month, -83.3% over six months, -90.9% over one year.

In the quarter ended Jun 30, 2026, revenue was $17K, with a net margin of -75000.0%.

Short interest was 427.4K shares at the Oct 15 settlement, down 12.3% from the prior report (4.1% of float, 1.0 days to cover).

Market cap$6.3M38.5M shares
Revenue · quarter$17.0K—
Diluted EPS$-0.41—
P/E · TTM—P/S 115.0×
Net margin-75,000.0%Gross 100.0%
Dividend yieldNone
52-week range0.16 – 2.39−93.1% from high
Volume286.1K0.03× 20-day avg
Volatility · 60d115.3%Annualised
Short % of float4.1%1.0 days to cover
Net cash$2.5MCash $6.5M
Next earnings—Not scheduled
Split-adjusted performance
1W −24.2%1M −50.2%3M −53.5%6M −83.3%YTD −84.2%1Y −90.9%3Y −94.1%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum5
Revenue growth—
Net margin1
Value (low P/E)—
Size7

Industry medians: 6-month return −24.8%, revenue growth +8.5%, net margin −226.4%, P/E 21.0×.

Short interest

Details →
Shares short427.4K−12.3% vs prior
Days to cover1.0Settled Oct 15
% of float4.1%
Short vol. 10d30.1%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
SNTISenti Biosciences Holdings$0.1645−6.85%−83.3%—−75000.0%—$6.3M
AIMAIM ImmunoTech$0.1521−5.53%−72.8%+4.0%−26876.9%—$6.1MCompare
INABIN8bio$0.8300−10.82%−48.1%———$8.2MCompare
CELZCreative Medical Technology Holdings$0.6059−7.05%−73.5%———$4.6MCompare
PMCBPharmaCyte Biotech$0.3752−1.52%−53.1%———$4.0MCompare
INTSIntensity Therapeutics$3.10−11.43%−39.3%———$10.1MCompare
PASGPassage Bio$3.46−1.42%−15.2%———$11.1MCompare
LIMNLiminatus Pharma$2.63−5.88%−73.8%———$3.5MCompare
SCLXScilex Holding$1.70−7.10%−78.9%−22.8%−1501.3%—$12.0MCompare

News about Senti Biosciences Holdings

All news →

No recent articles focused on Senti Biosciences Holdings.

Quick answers

What does Senti Biosciences Holdings do?
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments.
What is SNTI's market cap?
$6.33M, based on the Nov 5 close of $0.16.
Does Senti Biosciences Holdings pay a dividend?
No regular cash dividend has been paid in the last year.
How much of SNTI is sold short?
427.4K shares, 4.1% of float, as of Oct 15, 2026.
What sector is SNTI in?
Healthcare, in the Biotechnology industry.

About Senti Biosciences Holdings

Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).

HQ: South San Francisco, CA39 employeesListed Jun 9, 2022sentibio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology